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ABSTRACT 
 
The prevalence of obesity and obesity related diseases are increasing 
worldwide. Obesity is characterized by the pathological expansion of white 
adipose tissue. Previous studies on white adipose tissue of obese individuals 
have detected inflammation and fibrosis. These conditions may cause 
dysregulation of the tissue, leading to negative outcomes, including type II 
diabetes and metabolic syndrome.  
Aortic carboxypeptidase-like protein (ACLP) is a secreted extracellular 
matrix protein that is upregulated in fibrotic lung tissue. Importantly ACLP 
knockout mice are protected from experimentally induced lung fibrosis. ACLP is 
expressed in adipose tissue and is downregulated as stem cells undergo 
adipogenesis. Its overexpression increases α smooth muscle actin expression 
 v 
and impairs adipogenesis in preadipocyte lines; however, its role in white 
adipose tissue fibrosis has not been fully explored. 
The studies presented in this thesis aimed to investigate the hypothesis 
that ACLP overexpression in fibrotic white adipose tissue would promote a 
fibroblast to myofibroblast transition and repress adipogenesis. To determine if 
ACLP promotes a fibroblast to myofibroblast transition, we tested the capacity of 
ACLP to induce α smooth muscle actin and collagen I protein expression and 
increase contractility of primary stromal vascular cells. To assess the effects of 
ACLP on adipogenesis, we tested the ability of 10T1/2 fibroblasts and stromal 
vascular cells to undergo adipogenesis in collagen I gels under ACLP treatment. 
Results presented herein demonstrate ACLP is a potent inhibitor of 
adipogenesis and induces an upward trend in myofibroblast proteins and RNA 
expression. Significantly, these studies used murine adipose-derived cells to 
show the effects of ACLP, suggesting these results might be reflected in adipose 
tissue. These experiments support a model where ACLP potentiates adipose 
tissue fibrosis by inhibiting adipogenesis, resulting in fewer developing 
adipocytes, and stimulating myofibroblast differentiation, resulting in further 
collagen deposition and tissue compaction. This contribution to adipose tissue 
dysfunction also gives ACLP a possible role in the development of obesity 
related diseases, including diabetes and metabolic syndrome, identifying it as a 
possible target for therapeutics. 
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 1 
INTRODUCTION 
 
Obesity and Metabolic Syndrome 
 Obesity is a disease whose global prevalence is increasing at an alarming 
rate (Ogden et al., 2006; Rennie and Jebb, 2005; Svacina, 2012). White adipose 
tissue (WAT) plays a central role in the development of obesity. WAT acts as a 
repository for the storage of lipids and expands when there is a positive energy 
balance, i.e. when energy intake exceeds energy expenditure (Sethi and Vidal-
Puig, 2007). Obesity represents a state of prolonged positive energy balance 
resulting in pathological adipose tissue expansion, medically defined as a body 
mass index of 30 or higher (Flegal et al., 2013). 
 In obesity, WAT displays increased inflammation and fibrosis, resulting in 
dysregulation of the tissue (Trayhurn, 2013). These factors contribute to the 
development of metabolic syndrome, a grouping of several metabolic 
abnormalities, including high blood pressure, elevated triglycerides, and insulin 
insensitivity, which together increase the risk of cardiovascular disease and 
diabetes (Gorden et al., 2012; Maury and Brichard, 2010; Safar et al., 2013). 
 While the regulatory mechanisms of WAT are becoming better understood, 
there are still many unanswered questions about its function in fibrosis and 
disease. In order to understand the role of WAT in the development of obesity 
related pathological conditions, it is necessary to understand normal WAT 
function and its dysregulation in obesity. 
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Adipose Tissue 
 WAT is composed of numerous cell types, including adipocytes, fibroblasts, 
and endothelial and smooth muscle cells of blood vessels. Adipocytes are 
differentiated cells that are responsible for the lipid storage and metabolic activity 
of WAT. They contain large lipid droplets that fill the majority of the cell, with a 
smaller volume occupied by the nucleus, mitochondria, and other essential cell 
components. These cells are potent regulators of energy homeostasis in the 
body. In times when energy intake is greater than energy expenditure, 
adipocytes store lipids for future use. In times of energy deficit, intracellular lipids 
are catabolized and released for use by other organs (Wronska and Kmiec, 
2012). Through secretion of hormones (adipokines), including leptin and 
adiponectin, adipocytes also have an anti-inflammatory role and regulate both 
appetite and angiogenesis (Adya et al., 2012; Campfield et al., 1996). 
 The other cells of adipose tissue, which can be separated from adipocytes 
for further study, are designated the stromal-vascular fraction (SVF). The SVF 
includes a multitude of cell types that together support adipocytes. Among the 
many cell types are endothelial cells, fibroblasts, smooth muscle cells, immune 
cells, and stem cells (Peinado et al., 2012). Endothelial cells line blood vessels 
that carry oxygen and nutrients to adipocytes (Ouchi et al., 2011); immune cells 
defend against pathogens and clear dead cell debris (Cinti et al., 2005); and 
stem cells, given the proper stimulus, can differentiate into adipocytes (Ong and 
Sugii, 2013; Zuk et al., 2001, 2002). 
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Adipogenesis 
 Adipogenesis is a complex process that is still not clearly understood. In 
general, fibroblastic stem cells change from their spindly fibroblastic shape to a 
spherical one and accumulate lipid droplets. The origin of the mesenchymal stem 
cell (MSC) that gives rise to the preadipocyte may be from vascular pericytes in 
adipose tissue (Tang et al., 2008). However, it should be noted that not all 
pericyte-derived MSCs differentiate into adipocytes (Díaz-Flores et al., 1990; 
Diaz-Flores et al., 1991, 1992). Depending on tissue localization, molecular cues, 
and transcriptional regulators, MSCs can differentiate into a variety of other cell 
types (Collett and Canfield, 2005; Paul et al., 2012). 
 Adipogenic induction is still not fully understood; however, two 
transcriptional factors, CAAT/enhancer-binding protein (C/EBP)α and peroxisome 
proliferator-activated receptor (PPAR)γ are generally considered to be master 
regulators of the adipogenic program (Lane et al., 1996; Tontonoz et al., 1995). 
During adipogenesis, several genes are differentially regulated as part of a 
transcriptional regulatory cascade; however, induction of C/EBPs and PPARγ by 
upstream stimulators of adipogenesis occurs relatively early in the process (Brun 
et al., 1996). 
 C/EBPα is a transcriptional factor that has been widely studied for its role in 
adipogenesis. It is not an adipocyte specific protein; however, it is significantly 
upregulated just before many adipocyte specific genes are activated (Brun et al., 
1996; Mandrup and Lane, 1997). It forms homo- or heterodimers and binds to the 
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promoters of essential adipocyte genes, including those that code for the insulin 
receptor and the insulin-regulated glucose transporter, to induce their expression 
(Kaestner et al., 1990; McKeon and Pham, 1991). C/EBPα null mice fail to 
develop WAT (Wang et al., 1995), showing C/EBPα to be necessary for the 
development of mature adipocytes. 
 Expression of the transcription factor PPARγ is dramatically increased prior 
to the induction of several adipocyte-specific genes (Tontonoz et al., 1994). Its 
expression is required for the differentiation of adipocytes in vitro and in vivo 
(Barak et al., 1999; Rosen et al., 1999, 2002). PPARγ heterodimerizes with 
retinoic acid receptors or retinoid X receptors which in turn can bind DNA 
sequences termed PPAR response elements (Schoonjans et al., 1996a). PPARγ 
responds to a variety of ligands, including fatty acids and eicosanoids (Yu et al., 
1995), and once activated, induces several important adipocyte genes such as 
FABP4 that codes for fatty acid binding protein 4 (FABP4) (Tontonoz et al., 1994) 
and LPL, that codes for lipoprotein lipase (Schoonjans et al., 1996b). PPARγ is a 
potent stimulator of adipogenesis and is sufficient to induce transdifferentiation of 
other cell types, including myoblasts, into adipocytes (Teboul et al., 1995). 
 Fully differentiated adipocytes express and secrete a variety of 
components, including those essential for normal adipocyte function and energy 
homeostasis (Wronska and Kmiec, 2012). Adiponectin is a protein expressed 
and secreted by adipocytes (Hu et al., 1996; Scherer et al., 1995). Elevated 
circulating adiponectin levels correlate with greater insulin sensitivity and lower 
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body mass index (Hu et al., 1996; Yamauchi et al., 2001). Adiponectin may act 
by increasing β-oxidation of fatty acids in various tissues, including muscle 
(Bruce et al., 2005; Fruebis et al., 2001; Yamauchi et al., 2001). Adiponectin 
knockout mice exhibit several phenotypes, including hypertension, 
hyperlipidemia, and reduced insulin sensitivity (Kubota et al., 2002; Maeda et al., 
2002; Ouchi et al., 2003), highlighting adiponectin secretion as an important 
function of the mature adipocyte. 
 FABP4 is an intracellular lipid binding protein. FABP4 complexes with 
hormone-sensitive lipase (Gillilan et al., 2007; Smith et al., 2007) and acts as an 
intracellular fatty acid trafficking protein. Mice with FABP4 null mutations show 
decreased lipolytic activity and increased intracellular lipid accumulation (Coe et 
al., 1999; Hertzel et al., 2006); however, although they are still susceptible to 
diet-induced obesity, they do not develop the insulin resistance or cardiovascular 
disease normally associated with the obese phenotype (Hotamisligil et al., 1996; 
Layne et al., 2001a; Lehmann et al., 2004). 
 The development of mature adipocytes in WAT plays an important role in 
energy homeostasis and metabolic function. Therefore, disturbances in 
adipogenesis or WAT function by disease or injury can have severe 
consequences, including the development of cardiovascular disease and insulin 
insensitivity (Gorden et al., 2012; Safar et al., 2013). 
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Fibrosis 
 Tissue fibrosis is a condition characterized by the excessive deposition of 
extracellular matrix (ECM) proteins, such as collagens, by cells including 
fibroblasts and myofibroblasts. Buildup of fibrotic tissue in an organ can lead to 
dysfunction and ultimately, organ failure (Weber, 1997). Fibrosis is believed to be 
caused by chronic inflammatory responses induced by a variety of factors, such 
as chronic infections or tissue injury (Wynn, 2008; Wynn and Ramalingam, 
2012). Hypoxia is among the causes of inflammation related fibrosis in adipose 
tissue (Halberg et al., 2009; Trayhurn, 2013). Hypoxia is a state in which cells or 
tissues are supplied with insufficient oxygen to meet their metabolic needs. In 
adipose tissue, this can occur when adipocytes grow rapidly in times of 
excessive energy intake (obesity) and the vasculature fails to supply the 
expanded tissue and cells with oxygen due to diffusion limits. Hypoxia can result 
in cell and tissue necrosis, attracting leukocytes in an inflammatory response 
(Halberg et al., 2009; Trayhurn, 2013). The inflammatory response results in the 
local release of several “profibrotic” factors, particularly transforming growth 
factor β (TGF-β), that, over time, result in tissue fibrosis (Wynn and Ramalingam, 
2012). 
 Resident tissue fibroblasts can undergo a process called fibroblast to 
myofibroblast transition. Stimulated by growth factors, such as TGF-β, which is 
increased in obese murine adipose tissue (Samad et al., 1997), fibroblasts 
increase the expression of pro-contractile cytoskeletal elements, such as α 
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smooth muscle actin (αSMA), and the secretion of ECM proteins (Desmoulière et 
al., 1993; Shukla et al., 2013). In the context of wound healing, this activity helps 
to give structure and compact the damaged tissue, aiding the healing process 
(Hinz, 2010); however, improper regulation of this process can lead to an 
excessive amount of ECM deposition and non-functional tissue, i.e. fibrosis 
(Thiery, 2003). 
 
Adipose Tissue ECM 
 Adipocyte growth, including during obesity, requires remodeling of the ECM 
through several pathways (Chavey et al., 2003; Maquoi et al., 2002). Knockdown 
of MT1-MMP, a membrane anchored collagenase, results in smaller, improperly 
differentiated, multi-locular adipocytes (Chun et al., 2006). Decreased collagen I 
in fat pads of secreted protein acidic and rich in cysteine (SPARC)-null mice 
results in increased adipocyte size and number without increased overall body 
mass (Bradshaw et al., 2003). These findings underscore the importance of ECM 
structure and remodeling in adipocyte formation and growth. 
 A recent study using collagen VI knockout mice demonstrated the effect of 
ECM proteins on adipocyte development and expansion (Khan et al., 2009). The 
study showed that without collagen VI, the fat pads of mice fed a high fat diet 
expanded, resulting in improved insulin sensitivity and reduced inflammation. 
Khan et al. proposed that the improved phenotype is an effect of the reduction in 
ECM rigidity through the knockout of an ECM constituent, suggesting that the 
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rigidity of the ECM restricts the expansion of adipocytes. The authors also 
suggest a possible mechanism for obesity related inflammation and fibrosis 
(Khan et al., 2009). Due to an excessive caloric intake and metabolic stress, 
adipocytes grow at a rapid rate. In response to the stress of such a rapid 
expansion in a restrictive ECM, increased necrosis of stressed adipocytes 
induces an immunologically stressed state in the tissue, resulting in adipose 
fibrosis. This suggests that the rigidity of the ECM may restrict rapidly growing 
adipocytes in obesity and may be a significant factor in promoting a fibrotic state. 
 The emerging role of the ECM in WAT fibrosis provides significant insight 
into the cause and mechanism of disease; however, further understanding of 
how adipocytes and cells of the SVF interact with the components of the ECM is 
still necessary. 
 
Aortic Carboxypeptidase-Like Protein (ACLP) 
 ACLP is a secreted protein consisting of a signal peptide, lysine and proline 
rich extensin domain, a discoidin domain, and a catalytically inactive 
metallocarboxypeptidase domain at its C-terminus (Layne et al., 1998). The 
functions of most of the domains are not yet clearly understood; however, the 
discoidin domain has been shown to associate with the ECM (Schissel et al., 
2009), most likely through collagen binding. ACLP expression was originally 
noted in the vascular smooth muscle cells of adult murine aorta (Layne et al., 
1998). ACLP is important for organogenesis and murine fibroblasts lacking ACLP 
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are less proliferative and correlated with deficient wound healing (Layne et al., 
2001b). These findings support a role for ACLP in fibroblast proliferation and 
differentiation into active myofibroblasts. This fibroblast to myofibroblast transition 
is a classic characteristic of fibrotic tissue and indicative of a possible role for 
ACLP in tissue fibrosis. ACLP is highly upregulated in bleomycin-induced lung 
fibrosis (Schissel et al., 2009) and is histologically associated with areas 
expressing significant amounts of collagen. ACLP knockout mice exhibited a 4.8 
fold decrease in αSMA staining, greatly decreased collagen staining, and 28% 
less hydroxyproline content (an indicator of collagen content). This indicates that 
ACLP knockout mice were protected from severe fibrosis and myofibroblast 
accumulation, supporting the proposed role of ACLP in aggravating tissue 
fibrosis. 
 ACLP is expressed at low levels in adipose tissue, primarily in the SVF 
(Abderrahim-Ferkoune et al., 2004). Given the evidence that ACLP is secreted 
from the micro-vasculature (Hocking et al., 2010) and adipocyte precursors may 
arise from pericytes (Tang et al., 2008), it is possible that ACLP interacts with 
these precursors, either at the pericyte level or as MSCs in the stroma, and may 
be part of the adipogenic regulatory mechanism. 
 In vitro studies using 3T3 preadipocytes have shown that ACLP expression 
is regulated during the adipogenic process (Gagnon et al., 2002, 2005; 
Rodriguez et al., 2004), such that it is downregulated in the early stages of 
normal 3T3 preadipocyte differentiation. However, if ACLP is overexpressed in 
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3T3 cells, adipogenesis is inhibited and a transdifferentiation to smooth muscle-
like cells is induced (Abderrahim-Ferkoune et al., 2004). 
 
Cell Culture Substrata and 3 Dimensional Cell Culture 
 Traditional plastic culture is useful for creating in vitro models to study 
cellular processes and interactions; however, it has its limitations. Growing cells 
on plastic can induce morphological changes and alter protein expression 
patterns (Lee et al., 2013; Petersen et al., 1992). This can generate significant 
differences in the way cells behave compared to their true physiological behavior 
due to the altered stiffness of the environment. For example, 3T3-L1 adipocytes 
show reduced insulin sensitivity on culture surfaces with greater rigidity than that 
of adipose tissue (Li et al., 2009). Many studies have shown advantages to using 
ECM proteins to support adipogenesis, such as increases in the number and size 
of differentiating cells (Hausman et al., 1996; Hilliou et al., 1988; O’Connor et al., 
2003). 
 Additionally, in cell culture conditions where cells are plated on top of any 
culture surface, cells will attach only in a single layer (monolayer). Such a model 
deprives cells of many possible 3-dimensional ECM contacts formed in tissue. 
This is particularly problematic for cells, such as adipocytes, that require the 
structural support and modification of an ECM for proper differentiation or growth, 
(Chun et al., 2006; Stacey et al., 2009) and for proteins that interact with the 
ECM, such as ACLP (Schissel et al., 2009). To address this problem, a 3-
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dimensional model can be used. For example, a native conformation collagen I 
gel can be used as a cellular lattice, thereby generating a simplified ECM. 
Embedding cells within such a matrix allows both cells and proteins that interact 
with the ECM to better mimic their in vivo 3-dimensional environments 
(Cukierman et al., 2002; Griffith and Swartz, 2006). 
 
Goals of Thesis Research 
Considering the elevated expression of ACLP in lung fibrosis, a similar 
increase in ACLP expression could be expected in adipose tissue fibrosis. Given 
the structure of ACLP, the collagen binding discoidin region in particular, it could 
be expected to localize and bind to collagen rich regions throughout the fibrotic 
tissue and exert its effects. The goal of the studies presented in this thesis is 
to test the hypothesis that ACLP overexpression in fibrotic WAT would 
promote a fibroblast to myofibroblast transition and repress adipogenesis. 
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METHODS 
 
Recombinant Expression of ACLP 
 Recombinant ACLP was prepared in our laboratory by Kathleen Tumelty. 
Briefly, 293 cells were stably transfected with a plasmid encoding the BM40 
signal peptide-mouse ACLP followed by a myc-His tag. Cells were grown in 
SFM4HEK293 media. The spent medium was centrifuged at 3,220xg for 15 
minutes and the supernatant was retained and dialyzed using 100,000 molecular 
weight cutoff dialysis tubing for 36 hours into dialysis buffer (300 mM KCl, 50 mM 
KH2PO4, pH 8). Protein was purified using chromatography by passing dialyzed 
media through a Bio-Scale Mini Profinity IMAC Cartridge (Bio-Rad) using a Bio-
Rad Duo Flow and washed extensively using a 100 mM sodium carbonate buffer 
(pH 10.8). Protein was eluted with a 250 mM imidazole elution buffer. Eluted 
protein was concentrated and dialyzed into Phosphate Buffered Saline with 
Calcium and Magnesium (Mediatech). Protein concentration was determined 
using a Bradford assay and purity was verified by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis followed by Coomasie blue staining. 
 
Cell Isolation and Culture 
 SVF cells were isolated from discarded inguinal and epididymal adipose 
depots from male and female C57BL/6 mice 6-16 weeks of age using the 
following procedure. Fat pads were removed, minced, and digested with 100 
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µg/ml dispase (Becton Dickinson), 1 mg/ml collagenase (Worthington 
Biochemical) and 3 U/ml DNase (Worthington Biochemical). The digestion 
cocktail was neutralized using Dulbecco's modified Eagle medium (DMEM, 
Mediatech) supplemented with 10% fetal bovine serum (FBS, Hyclone), 100 U/ml 
penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine (PSG, Mediatech), and 4% 
bovine serum albumin (American Bioanalytical). Digested tissue was passed 
through a 100 µm cell strainer and centrifuged at 200xg for 10 minutes. The SVF 
pellet was resuspended in DMEM supplemented with 10% FBS and PSG (10% 
FBS DMEM). SVF cells were cultured at low passage (3 or less) in 10% FBS 
DMEM. 10T1/2 cells (American Type Culture Collection) were cultured in 10% 
FBS DMEM. All experiments used 10% FBS DMEM unless otherwise indicated. 
All ACLP treatments used 30 nM recombinant ACLP and all TGF-β treatments 
used 1 nM recombinant human TGF-β (R&D Systems). All cells were incubated 
at 37°C in a humidified atmosphere containing 5% CO2.  
 
Cell Contraction Assay 
 Passaged SVF cells were grown in 100 mm diameter plastic cell culture 
dishes (BD Falcon) and treated with 10% FBS DMEM (Control), 30 nM ACLP in 
10% FBS DMEM (ACLP), or 1 nM TGF-β in 10% FBS DMEM (TGF-β). After 3 
days, cells were released from dishes using 0.25% trypsin EDTA (Mediatech) 
and counted using a hemocytometer. Cell suspensions were pelleted by 
centrifugation at 200xg for 10 minutes, resuspended in DMEM supplemented 
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with 0.5% FBS and PSG, and mixed with rat tail Collagen I (BD) and Phosphate 
Buffered Saline (PBS, Mediatech) to achieve a final concentration of 400,000 
cells/ml and 1 mg/ml Collagen I. Polymerization of the mixture was initiated using 
23 µl 1N sodium hydroxide/ml volume of Collagen I used (regardless of 
concentration). The mixture was then plated into a 24-well cell culture plate (BD 
Falcon) in triplicate at 500 µl/well and allowed to set at 37°C for 30 minutes. Gels 
were covered with 10% FBS DMEM, gently separated from the sides of the well 
using a p200 pipet tip, and photographed at intervals. The area of wells and gels 
were measured using ImageJ. Percent contraction represents the difference 
between the area of the well and the area of the gel at the given time point. 
 
10T1/2 Adipogenesis in Collagen Gels 
 10T1/2 cells were grown in 100 mm diameter plastic cell culture dishes in 
10% FBS DMEM and treated at 80-90% confluence with 10% FBS DMEM 
(Control), 30 nM ACLP in 10% FBS DMEM (ACLP), and 1 nM TGF-β in 10% 
FBS DMEM (TGF-β). Media were changed daily for four days and cells reached 
confluence after two days. Cells were released from dishes using 0.25% trypsin 
EDTA and counted using a hemocytometer. The cell suspension was pelleted by 
centrifugation at 200xg for 10 minutes and resuspended in 0.5% FBS DMEM. 
The cell suspension was mixed with rat tail Collagen I and PBS to achieve a final 
concentration of 200,000 cells/ml and 1 mg/ml Collagen I. Polymerization and 
setting of the mixture was performed as described above. Cells were treated 
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immediately with an adipogenesis induction cocktail of 5 nM dexamethasone, 0.5 
mM 3-isobutyl-1-methylxanthine (IBMX), 4 nM insulin, and 12.5 µM indomethacin 
in 10% FBS DMEM (DMII) and experimental treatments: DMII (Control), 30 nM 
ACLP in DMII (ACLP), and 1 nM TGF-β in DMII (TGF-β). Every two days post-
induction, media were replaced with 1 nM insulin in 10% FBS DMEM (Control), 
30 nM ACLP and 1 nM insulin in 10% FBS DMEM (ACLP), and 1 nM TGF-β and 
1 nM insulin in 10% FBS DMEM (TGF-β). Protein samples were harvested 6 
days post-induction. 
 
SVF Adipogenesis in Collagen Gels 
 Isolated SVF cells were cultured in 150 mm diameter plastic cell culture 
dishes in 10% FBS DMEM for 2 days. Cells were released from dishes using 
0.25% Trypsin EDTA, counted, and set in collagen I gels as described above at a 
final concentration of 200,000 cells/ml and 1 mg/ml Collagen I. Cells were treated 
immediately with an adipogenesis induction cocktail of 0.25 µM dexamethasone, 
0.5 mM IBMX, and 8 nM insulin in 10% FBS DMEM (DMI) and experimental 
treatments: DMI (Control) and 30 nM ACLP in DMI. Two days post-induction, 
media were replaced with 1 nM insulin in 10% FBS DMEM (Control) and 30 nM 
ACLP and 1 nM insulin in 10% FBS DMEM (ACLP). RNA samples were 
harvested four days post-induction. 
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Protein Isolation and Western Blot Analysis 
For protein lysates from cells cultured on plastic, cells were washed twice 
with ice cold PBS and scraped on ice in Western extraction buffer (25 mM Tris 
pH 7.4, 50 mM sodium chloride, 0.5% sodium-deoxycholate, 2% IGEPAL CA-630 
octylphenyl-polyethylene glycol, 0.2% sodium dodecyl sulfate) with cOmplete 
mini protease and PhosSTOP phosphatase inhibitors (Roche). Lysates were 
clarified by centrifugation at 12,000xg for 10 minutes at 4°C.  
For cell lysates from cells embedded in gel, gels were washed twice with 
ice cold PBS, released from wells and placed in Pierce snap-cap spin columns 
(Thermo Scientific). Columns were filled with ice cold PBS and spun at 100xg for 
30 seconds repeatedly while discarding the flow through until it no longer 
changed color (usually within 3-5 washes). Western extraction buffer was added 
to the columns and the columns were sealed using Parafilm “M” (Pechiney). 
Columns were subjected to nutation overnight at 4°C then centrifuged at 6,000xg 
for 1 minute to collect extracted cell lysates. 
Quantification of protein was performed using the Pierce BCA Protein 
Assay Kit (Thermo Scientific), comparing cell lysates to a standard curve. Total 
protein from lysates was resolved on 4%-20% tris-glycine gels (Biorad) and 
transferred to a Protran nitrocellulose membrane (Whatman). Membranes were 
blocked using a solution of TBST (25 mM tris pH 8, 125 mM sodium chloride, 
0.1% tween 20) and 4% non-fat dry milk (LabScientific) (TBST-Milk). Membranes 
were incubated in primary antibodies overnight at 4°C. Primary antibodies used 
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include rabbit polyclonal ACLP antibody diluted 1:4000 (Layne et al., 1998), 
rabbit collagen I antibody (Rockland) diluted 1:4000, murine αSMA antibody 
(Sigma) diluted 1:2000, murine pan-actin antibody (Millipore) diluted 1:4000, 
rabbit adiponectin antibody (Affinity BioReagents) diluted 1:3000, rabbit FABP4 
antibody (Cell Signaling Technologies) diluted 1:1000, and rabbit PPARγ 
antibody (SantaCruz) diluted 1:200. After primary antibody incubation, 
membranes were washed briefly in TBST-Milk and incubated in horseradish 
peroxidase (HRP)-linked secondary antibodies (General Electric Healthcare) 
diluted 1:2500 for one hour. Membranes were washed briefly and secondary 
antibody was visualized using SuperSignal West Dura Extended Substrate 
(Thermo Scientific) or SuperSignal West Femto (Thermo Scientific) and imaged 
on a ChemiDoc XRS+ System (Bio-Rad). Some membranes were stripped 
following visualization using Western Stripping Buffer (Thermo Scientific) to allow 
for further blotting. All washes and incubations were performed with constant 
shaking. 
 
RNA Isolation, Reverse Transcription, and Real Time-Polymerase Chain 
Reaction (RT-PCR) Analysis 
RNA was isolated from SVF cells in collagen I gels using the RNeasy Mini Kit 
(Qiagen). In general, gels were washed twice with ice cold PBS, released from 
the wells, and dissolved in the RNA extraction buffer by overnight nutation at 
4°C. RNA was isolated using the protocol for isolation of RNA from mammalian 
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cells as per manufacturer’s instruction. RNA was quantified using the Take3 plate 
and Gen5 System (Biotek) as per manufacturer’s instruction. The Fermentas 
Maxima Reverse Transcriptase Kit (Thermo Scientific) and the Fermentas 
Maxima Probe Kit (Thermo Scientific) were used to reverse transcribe and 
amplify 500 ng of RNA as per manufacturer’s instruction. Primers used are 
indicated in Table 1. Samples were run on a 7300 Real Time PCR System 
(Applied Biosystems). Analysis was done using the delta-delta Ct method. 
 
Statistical Analysis 
Data are represented as mean ± standard deviation. Statistical significance was 
determined using either a two-way analysis of variance or two-tailed Student’s t-
test as indicated and defined p<0.05 as significant.  
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Table 1. Primers Used for RT-PCR 
Primers used for RT-PCR were obtained from Invitrogen  
Gene Name Forward Primer (5’-3’) Reverse Primer (5’-3’) 
18s CGGCTACCACATCCAAGGAA TTTTCGTCACTACCTCCCCG 
Col1a2 GTAACTTCGTGCCTAGCAACA CCTTTGTCAGAATACTGAGCAGC 
Col6a1 GATGAGGGTGAAGTGGGAGA CAGCACGAAGAGGATGTCAA 
Cebpa AAAGCCAAGAAGTCGGTGGACA CCTTCTGTTGCGTCTCCACGTT 
FABP4 AAGGTGAAGAGCATCATAACCCT TCACGCCTTTCATAACACATTCC 
Pparg GCATGGTGCCTTCGCTGA TGGCATCTCTGTGTCAACCATG 
Acta2 TGACGCTGAAGTATCCGATAGA GTACGTCCAGAGGCATAGAGG 
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RESULTS 
 
ACLP Increases Myofibroblast Protein Expression in SVF Cells 
 The fibroblast to myofibroblast transition is characterized by several 
changes in protein expression, most notably the induction of cytoskeletal and 
ECM protein expression, particularly αSMA and collagen I (Liu et al., 2012). 
These protein changes are accompanied by increased cellular contractility 
(Phan, 2008). 
 In fibrotic lung tissue, ACLP is associated with increased expression of 
αSMA and myofibroblast contractility and its knockout results in fewer αSMA 
positive fibroblasts and reduced fibrosis (Schissel et al., 2009). This suggests an 
ACLP-induced fibroblast to myofibroblast transition in lung fibrosis. The role of 
ACLP in adipose tissue fibrosis has not been well explored. Adipose tissue 
expression of ACLP may induce a fibroblast to myofibroblast transition in the 
resident fibroblasts of the tissue, promoting a “pro-fibrotic” phenotype. 
 To test this hypothesis, murine adipose tissue SVF cells were isolated, 
passaged to separate clusters, and treated with ACLP daily. Protein was 
harvested 2 and 3 days from initial treatment, resolved by Western blot, and 
analyzed for expression of αSMA and collagen I, markers of the myofibroblast 
phenotype (Figure 1). TGF-β is known to stimulate the fibroblast to myofibroblast 
transition and was used as a positive control. 
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Figure 1. ACLP Induces Myofibroblastic protein expression in SVF Cells.
Mixed adipose depots were excised from wild-type mice and SVF cells were 
isolated and plated as described in methods section. SVF cells were treated near 
confluence with 10% FBS DMEM (Control), 30nM rACLP in 10% FBS DMEM 
(rACLP), and 1nM rhTGF-β in 10% FBS DMEM (rhTGF-β). Media was replaced 
daily and cellular protein was  harvested at 2 and 3 from the initial treatment. Xug 
total protein was run on a 4-20% Tris-Glycine Gel. Following transfer, membrane 
was immunostained using antibodies against ACLP, Collagen I, αSMA, and Pan-
Actin. Treatment with rACLP and rhTGF-β seems to have no effect on ACLP 
expression at 2 or 3 days. Treatment with rACLP induces expression of Collagen 
I at 2 days; however, there is no distinguishable difference between treatment 
and control at 3 days. Treatment with rhTGF-β does not seem to affect Collagen I 
expression. Both rACLP and rhTGF-β induce αSMA expression at 2 and 3 days 
after initial treatment.
Control TGF-βACLP
Pan-actin
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αSMA
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Figure 1. ACLP Induces Myofibroblast Protein Expression in SVF Cells 
WAT fat pads were excised from wild-type mice and SVF cells were isolated, 
passaged, and plated into a 24-well cell culture plate. SVF cells were treated 
near confluence with 10% FBS DMEM (Control), 30 nM ACLP in 10% FBS 
DMEM (ACLP), and 1 nM TGF-β in 10% FBS DMEM (TGF-β). Media were 
replaced daily and cellular protein was harvested at 2 and 3 days from the initial 
treatment. Total protein (12 µg/lane) was run on a 4-20% tris-glycine gel, 
transferred to a nitrocellulose membrane, and probed with antibodies against 
ACLP, collagen I, αSMA, and pan-actin. These results are representative of data 
observed in three separate experiments using three separate SVF extractions. 
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 ACLP expression was not affected by treatments at 2 or 3 days. ACLP 
treatment slightly induced collagen I expression at 2 and 3 days. TGF-β had no 
effect on collagen I expression at 2 days, but slightly increased expression at 3 
days. Expression of αSMA was slightly induced by both ACLP and TGF-β at 2 
and 3 days. Results were reproducible across three separate experiments using 
cells from three separate extractions. 
 
ACLP Increases Contractility of SVF Cells Embedded in Collagen I Gels 
 Myofibroblasts show increased contractility, presumably due to the increase 
in cytoskeletal elements and matrix binding proteins (Hinz et al., 2001a, 2001b; 
Tomasek et al., 2002). Given the upward trend in αSMA expression in SVF cells 
exposed to ACLP, some increase in cell contractility was a likely outcome of 
ACLP treatment. An ACLP gain-of-function model increasing cell contractility 
would be consistent with findings that ACLP loss-of-function fibroblasts exhibit 
reduced contractility on collagen I gels (Schissel et al., 2009).  
 Several studies have assessed the contractility of various cells using 
collagen I contraction assays (Daniels and Khaw, 2000; Umino et al., 2000). To 
study ACLP-induced contractility, nearly confluent SVF cells were cultured on 
plastic and treated with ACLP or TGF-β. After 3 days of treatment, cells were 
embedded in a 1 mg/ml collagen I gel and released. Gel contractions were 
imaged at the indicated time points (Figure 2a) and analyzed to determine 
differences in cell contractility (Figure 2b). 
 23 
2 Hrs 24 Hrs8 Hrs6 Hrs 7 Hrs5 Hrs4 Hrs3 Hrs
C
on
tro
l
TG
F-
β
A
C
LP
Figure 2a. ACLP Increases Contractility of SVF Cells Embedded in 
Collagen I Gels
WAT fat pads were excised from wild-type mice and SVF cells  were isolated, 
passaged, and cultured in 100 mm diameter plastic cell culture dishes. SVF 
cells were treated near confluence with 10% FBS DMEM (Control), 30 nM 
ACLP in 10% FBS DMEM (ACLP), or 1 nM TGF-β in 10% FBS DMEM (TGF-
β) for 3 days. After 3 days, cells were plated in 1 mg/ml collagen I gels in 
triplicate at a concentration of 400,000 cells/ml. Gels  were gently released and 
photographed every hour from 2-8 hours and again at 24 hours post-release. 
These results are representative of data observed in two independent 
experiments using two separate SVF extractions.
 
Figure 2a. ACLP Increases Contractility of SVF Cells Embedded in Collagen 
I Gels 
WAT fat pads were excised from wild-type mice and SVF cells were isolated, 
passaged, and cultured in 100 mm diameter plastic cell culture dishes. SVF cells 
were treated near confluence with 10% FBS DMEM (Control), 30 nM ACLP in 
10% FBS DMEM (ACLP), or 1 nM TGF-β in 10% FBS DMEM (TGF-β) for 3 days. 
After 3 days, cells were plated in 1 mg/ml collagen I gels in triplicate at a 
concentration of 400,000 cells/ml. Gels were gently released and photographed 
every hour from 2-8 hours and again at 24 hours post-release. These results are 
representative of data observed in two independent experiments using two 
separate SVF extractions. 
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Figure 2b. ACLP Increases Contractility of SVF Cells Embedded in Collagen 
I Gels 
ACLP and TGF-β treated cells were embedded in collagen I gels and allowed to 
contract as described in Figure 2a. Gels were photographed every hour from 2-8 
hours and again at 24 hours post-release. Contracted gel images were analyzed 
using ImageJ. Measurements of well and gel areas were taken in arbitrary units 
for each image and compared. Percent contraction represents the difference 
between the area of the well (the original area of the gel) and the area of the gel 
at the given time point. Results represent average data for conditions in triplicate. 
At the earliest measured time point (2 Hours), gels with ACLP treated cells were 
156±3% more contracted than gels with control cells. Gels with TGF-β treated 
cells were 205±1% more contracted than gels with control cells. Both ACLP and 
TGF-β significantly increase SVF cell contractility in the first 24 hours post-
release as determined by a two-way analysis of variance (**p<0.001). 
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 Treatment with ACLP and TGF-β showed statistically significant increases 
in the contractility of SVF cells. At 2 hours post-release, ACLP and TGF-β treated 
cells exhibited 156±3% (p<0.001) and 205±1% (p<0.001) higher contraction, 
respectively, than control cells. The degree of gel contraction achieved by ACLP 
and TGF-β treated cells was consistently higher than that achieved by control 
cells in the first 24 hours post-release. These results are representative of two 
independent experiments using two separate SVF extractions. 
 
ACLP Decreases Expression of Differentiated Adipocyte Proteins in 10T1/2 
Cells 
 Having investigated the effects of ACLP on SVF cells, we next investigated 
the effects of ACLP on another component of adipose tissue, developing 
adipocytes. ACLP overexpression in 3T3 preadipocytes cultured on plastic has 
previously been shown to inhibit adipocyte differentiation and induce trans-
differentiation to a smooth muscle cell phenotype (Abderrahim-Ferkoune et al., 
2004). In contrast, other studies have shown that ACLP overexpression does not 
decrease adipocyte differentiation markers or affect morphology of 3T3-L1 
preadipocytes when induced to differentiate on plastic (Gagnon et al., 2005; 
Gusinjac et al., 2011). Furthermore 3T3-L1 preadipocytes overexpressing ACLP 
induced to undergo adipogenesis on a collagen I gel show decreased expression 
of fatty acid synthase, C/EBPα, and PPARγ compared to control cells (Gusinjac 
et al., 2011). Given the evidence that ACLP has a collagen binding discoidin 
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domain and associates with the ECM in fibrosis (Schissel et al., 2009), it is 
possible that the effects of ACLP on differentiating adipocytes may be, in part, 
mediated by ACLP binding to collagen and as a consequence, being presented 
to cells at a greater concentration. 
 Earlier in this study, ACLP treatment was shown to increase αSMA 
expression (Figure 1) and contractility (Figure 2) of SVF cells. This suggests a 
possible ACLP induced fibroblast to myofibroblast transition. Given this functional 
change and the evidence that αSMA expression is suppressed in cells committed 
to adipogenesis (Okada et al., 2012), it is possible that ACLP exposure before 
and during adipogenesis may promote a myofibroblastic phenotype in adipocyte 
precursors and prevent adipogenesis. Noting that ACLP overexpression impairs 
adipogenesis of preadipocytes cultured on top of prepared collagen I gels and 
the possibility that the effects of ACLP on adipogenesis may be mediated by 
ECM binding, we hypothesized ACLP would hinder adipogenesis of cells 
embedded in a collagen I gel. 
 To test this hypothesis, 10T1/2 cells were incubated in ACLP or TGF-β for 
four days, embedded in a 1 mg/ml collagen I gel, and induced to undergo 
adipogenesis as described in the methods section. TGF-β is a known inhibitor of 
adipogenesis and is expressed in obese adipose tissue (Choy and Derynck, 
2003; Samad et al., 1997). Protein samples were harvested 6 days post-
induction and analyzed by Western blot. The blot was probed with antibodies  
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Figure 3. Pre-Induction ACLP Treatment Results in Decreased Expression 
of Adiponectin, FABP4, and PPARγ in Differentiating 10T1/2 Cells 
10T1/2 cells were cultured in 100 mm diameter plastic cell culture dishes and 
treated near confluence with 10% FBS DMEM (Control), 30 nM ACLP in 10% 
FBS DMEM (ACLP), and 1 nM TGF-β in 10% FBS DMEM (TGF-β). Media were 
changed daily for four days, at which time cells were plated in a 1 mg/ml collagen 
I gel and treated immediately with 5 nM dexamethasone, 0.5 mM IBMX, 4 nM 
insulin, and 12.5 µM indomethacin in 10% FBS DMEM (DMII) and treatments: 
DMII (Control), 30n M ACLP in DMII (ACLP), and 1 nM TGF-β in DMII (TGF-β). 
Every two days post-induction, media were replaced with 1 nM insulin in 10% 
FBS DMEM (Control), 30 nM ACLP and 1 nM insulin in 10% FBS DMEM (ACLP), 
and 1 nM TGF-β and 1 nM insulin in 10% FBS DMEM (TGF-β). Protein samples 
were harvested 6 days post-induction. Total protein (16 µg/lane) was resolved by 
Western blot and probed with antibodies against adiponectin, FABP4, PPARγ, 
αSMA, and pan-actin. Results represent a single preliminary experiment. 
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against adiponectin, FABP4, and PPARγ, markers of differentiated adipocytes, 
as well as αSMA (Figure 3). 
 It should be noted the extraction of cellular protein from within a collagen I 
gel requires the extraction of FBS components that accumulate within the gel and 
are not removed by media changes or simple washes of the gel. Resolution of 
protein samples with significant FBS content results in protein smears as 
observed by Coomasie blue and non-specific antibody staining (data not shown). 
To obtain clear bands by Western blot and Coomasie blue staining, 
centrifugation in spin columns at low speeds and at 4°C was used to force some  
of the media containing FBS out of the gel. By placing the gel in PBS for each 
centrifugation, more media washed out of the gel, as evidenced by the color of 
the flow-through. Once flow-through no longer changed color, resolution 
consistently gave clear bands by Western blot and Coomasie blue staining (data 
not shown). 
 Cells treated with ACLP and TGF-β exhibited drastically decreased 
expression of adiponectin, FABP4, and PPARγ expression. Expression of αSMA 
was similar for treatments and controls. Inspection of the cells before harvest 
under a microscope showed visible adipocytes among control cells, but few/none 
in the ACLP and TGF-β treated cells (data not shown). Results represent a single 
preliminary experiment.  
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ACLP Induces Acta2 and Collagen Gene Expression and Reduces 
Expression of Adipogenic Genes in Differentiating SVF cells 
 ACLP slightly increased αSMA and collagen I expression in SVF cells 
(Figure 1), indicative of a possible fibroblast to myofibroblast transition. ACLP 
also impaired 10T1/2 cell adipogenesis (Figure 3). This inhibition may be 
mediated by changes in RNA levels. TGF-β inhibits adipogenesis by repressing 
C/EBP transcriptional activity through Smad signaling (Choy and Derynck, 2003). 
ACLP may promote a fibroblast to myofibroblast transition and inhibit 
adipogenesis at a transcriptional level by increasing transcription of genes 
associated with myofibroblasts and decreasing transcription of genes associated 
with adipocytes. 
 To test this hypothesis, isolated SVF cells were cultured for 2 days on 
plastic, then embedded in 1 mg/ml collagen I gels. Cells were induced to 
differentiate and treated with ACLP in quadruplicate (see methods section). RNA 
samples were harvested four days post-induction to observe levels of Pparg and 
Cebpa, which are upregulated early in adipogenesis. Total RNA was subjected to 
reverse transcription and RT-PCR (Figures 4 and 5). 
 Treatment with ACLP increased Acta2 (the gene for αSMA) RNA levels to 
132.29% and Col6a1 to 139.03% compared to controls (Figure 4); however 
neither of these differences were statistically significant (p=0.46 and p=0.08, 
respectively). Treatment significantly increased expression of Col1a2 RNA to 
194.44% compared to controls (Figure 4). Treatment with ACLP significantly 
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Fig 4. ACLP Induces Acta2 and Collagen Gene Expression in Differentiating 
SVF cells 
Isolated SVF cells were cultured on 150 mm diameter plastic cell culture dishes 
for 2 days then embedded in 1 mg/ml collagen I gels in quadruplicate. Cells were 
treated immediately with 0.25 µM dexamethasone, 0.5 mM IBMX, and 8 nM 
insulin in 10% FBS DMEM (DMI) (Control) or 30 nM ACLP in DMI (ACLP). Two 
days post-induction, media were replaced with 8 nM insulin in 10% FBS DMEM 
(Control) or 30 nM ACLP and 8 nM insulin in 10% FBS DMEM (ACLP). RNA was 
harvested four days post-induction (see methods). Total RNA (500 ng) was 
subjected to reverse transcription and RT-PCR. Treatment with ACLP increased 
expression of Acta2, Col1a2, and Col6a1 to 132.29%, 194.44%, and 139.03%, 
respectively. Statistical significance was determined using a two-tailed Student’s 
t-test (*p<0.05). Results represent a single preliminary study. 
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Fig 5. ACLP Suppresses Adipogenic Gene Expression in Differentiating 
SVF cells 
Isolated SVF cells were treated and harvested for RNA as in Figure 4. Total RNA 
(500 ng) was subjected to reverse transcription and RT-PCR. Treatment with 
ACLP significantly decreased expression of Cebpa, FABP4, and Pparg RNA to 
44.93%, 2.78%, and 0.82%, respectively. Statistical significance was determined 
using a two-tailed Student’s t-test (*p<0.05, **p<0.001). Results represent a 
single preliminary study. 
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decreased expression of Cebpa, FABP4, and Pparg RNA to 44.93%, 2.78%, and 
0.82%, respectively, compared to controls (Figure 5). These results represent a 
single preliminary study. 
 The preliminary studies presented in these results demonstrate that ACLP 
treatment 1) induces an upward trend in the expression of proteins and RNA 
characteristic of myofibroblasts and 2) significantly suppresses adipogenesis at 
both the protein and RNA level. 
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DISCUSSION 
 
This study set out to determine the effects of ACLP on SVF cells and 
differentiating adipocytes, testing the hypothesis that ACLP would induce a 
fibroblast to myofibroblast transition in SVF cells and inhibit adipogenesis. 
The results presented in this study suggest ACLP may be capable of inducing a 
myofibroblastic phenotype in SVF cells. These studies also indicate that ACLP is 
a potent inhibitor of adipogenesis. These findings may serve as the basis for 
further experiments determining the role of ACLP in WAT fibrosis and suggest a 
possible target for improving or preventing obesity-induced WAT fibrosis and its 
consequent disease symptoms. 
 
ACLP Induced Fibroblast to Myofibroblast Transition 
 ACLP plays a significant role in the development of bleomycin-induced lung 
fibrosis (Schissel et al., 2009). In fibrotic lung tissue, elevated ACLP expression 
was associated with areas of high collagen deposition. ACLP knockout mice 
were protected from severe lung fibrosis and exhibited decreased collagen I 
deposition and αSMA expression. ACLP knockout fibroblasts also showed 
decreased contractile activity. This suggests ACLP expression is necessary for 
the induction or activation of these fibroblasts to contractile, collagen secreting 
myofibroblasts. In a 3T3 preadipocyte model, ACLP overexpressing cells have 
shown the capacity to differentiate into αSMA expressing cells (Abderrahim-
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Ferkoune et al., 2004). This study expands these findings to SVF cells from 
murine adipose tissue. It also adds the ability of ACLP to slightly induce collagen 
I expression and significantly increase cell contractility (Figures 1 and 2). These 
are hallmarks of activated myofibroblasts (Phan, 2008) and are similar to the 
effects of ACLP observed in fibrotic lung tissue. 
 The upward trend in myofibroblast proteins and RNA levels with ACLP 
treatment support the idea that ACLP may be inducing a fibroblast to 
myofibroblast transition. It is possible that under different experimental 
conditions, a greater difference in expression might be seen. For example, cell 
culture surface rigidity induces αSMA expression in cells (Huang et al., 2012; 
Schlunck et al., 2008). Culturing cells on softer surfaces throughout experiments 
might reduce non-treatment induction of αSMA, highlighting the difference in 
αSMA expression between control and treatment conditions. Further studies are 
needed to determine the efficacy of ACLP-induced myofibroblast differentiation. 
 In any case, this finding in adipose stromal cells certainly suggests that 
ACLP-induced fibroblast to myofibroblast transition may occur in WAT and play a 
significant role in WAT fibrosis. In parallel with fibrotic lung tissue, increased 
ACLP expression associated with the increased collagen I deposition can be 
expected in fibrotic WAT tissue. Increased ACLP localization with collagen I 
throughout fibrotic tissue is most likely an effect of its collagen I binding discoidin 
domain (Schissel et al., 2009). It is possible that continuous binding to the 
collagen I ECM would create an increase in local ACLP concentration, 
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compounding its effects. In fibrotic WAT, this might create a concentrated or 
localized region of ACLP expression which is different from its normal expression 
in the microvasculature (Hocking et al., 2010). This irregular exposure of ACLP in 
tissue may result in greatly increased myofibroblast differentiation in the stroma. 
The increased number of myofibroblasts would alter tissue structure in two ways. 
Firstly, the increase in ACLP-induced myofibroblasts would result in increased 
deposition of collagen I in the ECM. Secondly, through increased contractility, 
these cells would compact the tissue. Both of these methods have the effect of 
increasing the ECM density, the amount of ECM proteins in a given area. 
Adipocyte hypertrophy, like that seen in obesity, is normally associated 
with inflammatory responses as a result of increased adipocyte necrosis (Cinti et 
al., 2005). Chronic inflammatory responses to this necrosis exacerbate adipose 
tissue inflammation (Wynn, 2008; Wynn and Ramalingam, 2012). Knockout of 
collagen VI or SPARC results in mice with increased adiposity without the 
associated inflammation (Bradshaw et al., 2003; Khan et al., 2009). This 
suggests increased ECM density is more restrictive to adipocyte growth and may 
be inversely correlated with expansion related inflammation and fibrosis. Given 
the evidence that ACLP may increase ECM density and its knockout protects 
tissue from severe fibrosis, ACLP may aggravate fibrosis and inflammation in 
WAT. 
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ACLP Impairs Adipogenesis 
 ACLP inhibits adipogenesis through suppression of the key regulators, 
PPARγ and C/EBPα. Results in this study show ACLP exposure causes a drastic 
decrease in PPARγ and FABP4 protein expression in differentiating 
preadipocytes (Figure 3). Importantly, ACLP caused reductions in Pparg, Cebpa, 
and FABP4 RNA expression in SVF cells induced to undergo adipogenesis 
(Figure 5). This demonstrates that ACLP is able to inhibit adipogenesis in murine 
adipose-derived cells. Evidence in the literature on the effects of ACLP 
overexpression in preadipocytes is conflicting. Abderrahim-Ferkoune et al. have 
shown ACLP overexpression to decrease PPARγ2 and FABP4 RNA levels, 
resulting in an inability to differentiate into adipocytes. This is consistent with the 
suppression seen in our studies. Interestingly, Gusinjac et al. reported no effects 
of ACLP overexpression on cells induced to differentiate on tissue culture plastic, 
but a suppression of C/EBPα, PPARγ, and fatty acid synthase was observed in 
ACLP overexpressing cells induced on a collagen I coated surface. However, 
unpublished studies from our lab show that ACLP treatment is indeed inhibitory 
to cells induced on plastic as measured by decreased Oil Red O staining and 
drastically decreased PPARγ and FABP4 protein expression. This difference 
could be explained by different concentrations of ACLP in the experiments. Our 
lab used a recombinant form of ACLP at 30 nM, whereas the concentration of 
ACLP from overexpressing 3T3 cells was not reported, but may have been lower 
considering the lack of effect in cells cultured on plastic. In their studies, the 
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observed effects of ACLP overexpression on cells cultured on a collagen surface 
may have been mediated by ACLP binding the collagen. As described above, 
this may increase local concentration of ACLP and prevent its removal from 
culture through media changes. Therefore, the cells on the collagen surface 
would be exposed to a greater local concentration of ACLP, resulting in stronger 
anti-adipogenic effects. 
 Increased ability of ACLP to inhibit adipogenesis through collagen I binding 
suggests that ACLP binding in fibrotic tissue would result in greater local 
concentrations, exerting an anti-adipogenic effect in areas that might normally 
promote adipogenesis. This effect may be compounded by continued ACLP 
binding in the course of fibrotic disease. 
 This observation has significant impact for obesity-induced WAT fibrosis. 
Considering the increased necrotic rate in obese WAT (Cinti et al., 2005), an 
increased adipogenic rate would be needed to generate new adipocytes in order 
to compensate for adipocytes lost to necrosis. In heavily fibrotic adipose tissue, 
collagen-bound ACLP would inhibit adipogenesis, preventing such 
compensation. This would correspond to greater decreases in circulation of 
adipokines, such as adiponectin, and greater increases in circulating free fatty 
acids, which have been linked to several disease symptoms, including insulin 
resistance, type II diabetes mellitus, and heart disease (Jensen, 2006; Weyer et 
al., 2001; Yamauchi et al., 2001). 
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Adipocyte and Myofibroblast Differentiation 
 MSCs of adipose tissue are capable of differentiating into a variety of cell 
types, including adipocytes and myofibroblasts (Gimble and Guilak, 2003; Zuk et 
al., 2001, 2002). However, evidence in the literature suggests that the stimulants 
of adipogenesis are inhibitory to myofibroblast differentiation and vice versa 
(Hong et al., 2007). PPARγ ligands inhibit TGF-β-induced myofibroblast 
differentiation through the blockade of several pathways, some of which are even 
PPARγ independent (Ferguson et al., 2009; Kuriyan et al., 2012). Similarly, TGF-
β stimulation inhibits the adipogenic program through the impairment of PPARγ 
activity as well as the expression and nuclear localization of C/EBPα (Choy and 
Derynck, 2003; Kumar et al., 2012). Differentiated myofibroblasts are highly 
contractile cells as a function of increased αSMA expression, induced as part of 
their differentiation program (Phan, 2008). Adipocytes, on the other hand, 
specifically decrease their expression of αSMA as part of the adipogenic program 
(Okada et al., 2012). This suggests that the pathways leading from precursors to 
adipocytes and myofibroblasts are conflicting and unlikely to be activated and 
followed simultaneously. 
 Results from this study support this model. ACLP was shown to induce an 
upward trend in the expression of myofibroblast genes and proteins. It was also 
demonstrated to strongly inhibit expression of adipocyte genes and proteins. This 
suggests ACLP inhibits adipogenesis and may simultaneously promote 
myofibroblast differentiation. 
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 Seemingly contrasting with the idea that ACLP induces myofibroblast 
differentiation and inhibits adipogenesis, αSMA expression was similar between 
control and ACLP treated conditions (Figure 3), indicative of equivalent 
myofibroblast presence in both ACLP and control conditions. This result is 
confusing however, considering the difference in adipocyte protein expression 
between control and ACLP conditions. This may be explained by the 
development of a heterogeneous mixture of cells, only some of which retained 
adipogenic potential. It is possible that four days of culture on rigid plastic 
surfaces may have induced significant αSMA expression (Huang et al., 2012; 
Schlunck et al., 2008), reflecting ACLP-independent myofibroblast differentiation, 
across control and treatment conditions. In this case, total αSMA expression in 
this particular experiment may not be useful for determining the myofibroblast 
inducing effects of ACLP, as the change in αSMA induced by ACLP may have 
been small or negligible compared to the degree of overall αSMA expression. 
However, the drastic decrease in adipocyte proteins in the ACLP condition 
indicates that ACLP inhibited adipogenesis of the cells that retained adipogenic 
potential. 
 Immunohistochemistry and fluorescence imaging studies could be used to 
test the hypothesis that these two pathways are mutually exclusive and result in 
a heterogeneous population of cells by determining if the localization of αSMA 
and FABP4 are primarily in different cells. 
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Targeting ACLP in Obesity-Induced WAT Fibrosis 
 Obesity-induced WAT fibrosis and inflammation are serious conditions 
linked with several disease states, most notably insulin insensitivity and type II 
diabetes (Jensen, 2006; Weyer et al., 2001; Yamauchi et al., 2001). Considering 
the significant and detrimental effects of WAT fibrosis, understanding the 
mechanism of this disease and identifying key pathways will give insight into 
possible treatments and cures and perhaps even a way to prevent it. 
 Evidence presented in this study suggests ACLP may play a role in 
aggravating tissue fibrosis and subsequent disease states in obesity-induced 
WAT, identifying it as a possible therapeutic target. ACLP’s mechanism of action 
is not yet well defined; however, responses to ACLP treatment are similar to 
those observed from TGF-β treatment (Figures 1-3). In fact, TGF-β regulates 
ACLP expression in 3T3 cells (Gagnon et al., 2005; Schissel et al., 2009). 
Though further studies will be necessary to elucidate ACLP mechanisms of 
action, similarities between responses to TGF-β and ACLP indicate some 
possibilities. 
1) ACLP and TGF-β may have an overlapping pathway, sharing some of 
the same signaling molecules.	  
2) ACLP may activate the TGF-β receptor.  
3) ACLP may enhance TGF-β binding to its receptor.  
4) ACLP may increase expression of TGF-β through enhanced 
transcription or repressed degradation. 
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Figure 6. Proposed Model of ACLP Aggravation of Fibrosis 
ACLP is hypothesized to aggravate fibrosis by (A) inhibiting adipogenesis and 
inducing myofibroblast differentiation of stromal precursor cells. (B) Increased 
ACLP expression, associated with the increased collagen I deposition in fibrosis, 
induces myofibroblast differentiation of stromal cells. The increased number of 
myofibroblasts causes increased collagen deposition and tissue compaction, 
resulting in adipocyte necrosis. Adipocyte necrosis induces an immune response, 
which in turn stimulates further tissue fibrosis. 
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CONCLUSIONS 
 
 This study has presented preliminary findings indicating ACLP may induce 
the expression of myofibroblastic proteins and inhibits the expression of 
adipogenic genes in murine adipose derived cells. Inhibition of adipogenic gene 
expression by ACLP was supported by protein data from 10T1/2 cells. These 
results suggest a role for ACLP in aggravating obesity-induced WAT fibrosis and 
indicate it as a possible therapeutic target. Further investigations will elucidate 
the function of ACLP in fibrotic WAT and the mechanisms of ACLP action and 
may lead to treatments for adipose tissue dysfunction. 
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